Kringle Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-914	-754	-852	-330	-299
Other Operating Activities	130	155	147	341	84
Change in Accounts Receivable	-	7	-7	6	99
Change in Inventory	44	69	-14	-34	-268
Change in Accounts Payable	-16	-135	118	21	-41
Change in Other Net Operating Assets	1	-3	-81	11	-135
Operating Cash Flow	-755	-661	-689	15	-560
Investment in Securities	-131	-121	-120	-254	-
Other Investing Activities	-23	-	-	-	-
Investing Cash Flow	-154	-121	-120	-254	-
Issuance of Common Stock	84	838	69	603	612
Other Financing Activities	-	-	-	-	-17
Financing Cash Flow	84	838	69	603	595
Miscellaneous Cash Flow Adjustments	-	-1	-	-	-1
Net Cash Flow	-825	55	-740	364	34
Cash Income Tax Paid	1	1	1	-6	1
Levered Free Cash Flow	-581.13	-552.63	-538.63	-185.25	-505.75
Unlevered Free Cash Flow	-581.13	-552.63	-538.63	-185.25	-505.75
Change in Working Capital	29	-62	16	4	-345

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.